Premium
Strategies to optimize the use of targeted agents for tumor therapy
Author(s) -
Becker Jürgen C.,
Ugurel Selma,
Schrama David
Publication year - 2008
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2008.06496.x
Subject(s) - medicine , targeted therapy , radiation therapy , cancer therapy , cancer , combination therapy , broad spectrum , intensive care medicine , bioinformatics , pharmacology , biology , chemistry , combinatorial chemistry
Summary In recent years the traditional treatment spectrum of tumors – chemotherapy or radiotherapy – has been extended with immune‐modulating strategies.For some tumors, clinical responses have been observed but for numerous others no satisfactory approach has been established. Many new agents have been developed;the targeted or smart drugs modulate a constantly growing list of tumor‐specific signal pathways and represent an enormous hope for cancer patients.The clinical evaluation of these targeted drugs alone or in combination also presents an enormous challenge.Since the number of possible combinations of targeted drugs seems almost limitless, an accurate strategy for determination of success‐promising combination patterns for the individual cancer patient is of special importance.